Alpha 2.0
Login Register
» Authors » Akil A Kalathil

Akil A Kalathil

Explore the profile of Akil A Kalathil including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 97
Followers 0
Related Specialties
Chemistry
Biotechnology
Biochemistry
Top 10 Co-Authors
Shanta Dhar
Bapurao Surnar
Nagesh Kolishetti
Akash Ashokan
Mohammad Z Kamran
Michal Toborek
Leonor M Lima
Madhavan Nair
Minseon Park
Royden Ramirez Jaime
Published In
ACS Cent Sci
ACS Nano
Chem Commun (Camb)
Mol Aspects Med
Chemosphere
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction to "Brain-Accumulating Nanoparticles for Assisting Astrocytes to Reduce Human Immunodeficiency Virus and Drug Abuse-Induced Neuroinflammation and Oxidative Stress"
Surnar B, Shah A, Park M, Kalathil A, Kamran M, Ramirez Jaime R, et al.
ACS Nano . 2024 Aug; 18(33):22608. PMID: 39110088
No abstract available.
2.
Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites
Ashokan A, Sarkar S, Kamran M, Surnar B, Kalathil A, Spencer A, et al.
Proc Natl Acad Sci U S A . 2024 May; 121(20):e2318119121. PMID: 38709930
Brain metastasis of advanced breast cancer often results in deleterious consequences. Metastases to the brain lead to significant challenges in treatment options, as the blood-brain barrier (BBB) prevents conventional therapy....
3.
Correction to "New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance"
Kalathil A, Guin S, Ashokan A, Basu U, Surnar B, Delma K, et al.
ACS Cent Sci . 2023 Aug; 9(8):1705. PMID: 37637725
[This corrects the article DOI: 10.1021/acscentsci.3c00286.].
4.
New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance
Kalathil A, Guin S, Ashokan A, Basu U, Surnar B, Delma K, et al.
ACS Cent Sci . 2023 Jul; 9(7):1297-1312. PMID: 37521786
Tumor cells adapt to diverse survival strategies defying our pursuit of multimodal cancer therapy. Prostate cancer (PCa) is an example that is resistant to one of the most potent chemotherapeutics,...
5.
Controlled release nanoplatforms for three commonly used chemotherapeutics
Costoya J, Surnar B, Kalathil A, Kolishetti N, Dhar S
Mol Aspects Med . 2021 Dec; 83:101043. PMID: 34920863
In order to combat an evolving, multidimensional disease such as cancer, research has been aimed at synthesizing more efficient and effective versions of popular chemotherapeutic drugs. Despite these efforts, there...
6.
Brain-Accumulating Nanoparticles for Assisting Astrocytes to Reduce Human Immunodeficiency Virus and Drug Abuse-Induced Neuroinflammation and Oxidative Stress
Surnar B, Shah A, Park M, Kalathil A, Kamran M, Ramirez Jaime R, et al.
ACS Nano . 2021 Aug; 15(10):15741-15753. PMID: 34355558
Human neurotropic immunodeficiency virus (HIV) ingress into the brain and its subsequent replication after infection results in viral reservoirs in the brain. The infected cells include microglia, perivascular macrophages, and...
7.
Per- and polyfluoroalkyl substances and fluorinated alternatives in urine and serum by on-line solid phase extraction-liquid chromatography-tandem mass spectrometry
Kato K, Kalathil A, Patel A, Ye X, Calafat A
Chemosphere . 2018 Jun; 209:338-345. PMID: 29935462
Per- and polyfluoroalkyl substances (PFAS), man-made chemicals with variable length carbon chains containing the perfluoroalkyl moiety (CF-), are used in many commercial applications. Since 1999-2000, several long-chain PFAS, including perfluorooctane...
8.
New formulation of old aspirin for better delivery
Kalathil A, Kumar A, Banik B, Ruiter T, Pathak R, Dhar S
Chem Commun (Camb) . 2015 Oct; 52(1):140-3. PMID: 26503669
For better use of cyclooxygenase dependent anti-inflammatory properties and mitochondrial activities of aspirin, new hydrophobic analogues of aspirin were developed and successfully encapsulated in polymeric nanoparticles (NPs). In vivo anti-inflammatory...